Ziftomenib Maintenance Post Allo-HCT

The purpose of this study is to test the safety, effects, and recommended dose of an investigational drug, ziftomenib, in addition to the standard treatment on blood cancer with Allogeneic Hematopoietic Cell Transplantation (allo-HCT). This study plans to learn more about ziftomenib, which targets and inhibits negative interactions within cancer cells related to AML, when given after allo-HCT, to determine if it improves outcomes following allo-HCT. The name of the study drug involved in this study is: • Ziftomenib

Trial Details

NCT ID
NCT06440135
Phase
PHASE1
Sponsor
Massachusetts General Hospital
Status
RECRUITING
Cancer Type
Acute Myeloid (AML) Leukemia
Interventions
  • Ziftomenib
Locations (sample)
  • Boston, Massachusetts, United States|42.35843,-71.05977
  • Columbus, Ohio, United States|39.96118,-82.99879

Key Eligibility Criteria

  • 18 years or older.
  • Pathologically confirmed diagnosis of acute myeloid leukemia (AML).
  • Complete remission (CR) or complete remission with incomplete count recovery (CRi) at screening.
  • Complete remission (CR):

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Acute Myeloid (AML) Leukemia Trials on Trialify →